L’épisode le plus récent
What’s New in Hematology/Oncology? Discussing the 2025 ASH Annual Meeting After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP
Durée : 28:02
After the 2025 American Society of Hematology (ASH) Annual Meeting had passed, the data were out, and the hematologist/oncologists of the world had time to digest the practice changes that awaited them upon their returns home. Rahul Banerjee, MD, FACP, and Brooke Adams, PharmD, BCOP, took part in an X Spaces discussion hosted by CancerNetwork® in collaboration with The American Society for Transplantation and Cellular Therapy (ASTCT) to highlight these potential changes.
Adams and Banerjee discussed abstracts from the meeting, including the phase 3 MajesTEC-3 trial (NCT05083169), which evaluated teclistamab-cqyv (Tecvayli) plus daratumumab (Darzalex) in patients with relapsed/refractory multiple myeloma who progressed on at least 1 prior line of therapy.1 A significant progression-free survival benefit was observed with the experimental combination compared with standard of care in this population.
They also discussed data from cohort A of the phase 2 IFM2021-01 trial (NCT05572229), which evaluated subcutaneous teclistamab in combination with subcutaneous daratumumab in patients with newly diagnosed multiple myeloma. Results demonstrated that the combination was effective and safe in the frontline treatment of patients who were ineligible for transplant.2
The discussion also covered the broader treatment landscape, as the experts compared the use of bispecific antibodies with BCMA-directed CAR T-cell therapies. Frontline bispecific strategies for transplant-ineligible populations were also topics of conversation, as well as post-transplant consolidation with bispecifics. Ultimately, they stated that multiple myeloma care is undergoing a paradigm shift toward deeper minimal residual disease negativity, possible treatment de‑escalation, and even serious use of the word “cure” for the disease.
Banerjee is an assistant professor in the Clinical Research Division at the Fred Hutchinson Cancer Center, and Adams is a clinical pharmacist in the Department of Stem Cell Transplant and Cellular Therapy and coordinator of the PGY-2 Oncology Residency at Orlando Health. Both are also members of the ASTCT content committee.
References
Mateos M-V, Bahlis N, Perrot A, et al. Phase 3 randomized study of teclistamab plus daratumumab versus investigator’s choice of daratumumab and dexamethasone with either pomalidomide or Bortezomib (DPd/DVd) in patients (Pts) with relapsed refractory multiple myeloma (RRMM): Results of majestec-3. Blood. 2025;146(suppl 2):LBA-6. doi:10.1182/blood-2025-LBA-6
Manier S, Lambert J, Marco M, et al. A phase 2 study of teclistamab in combination with daratumumab in elderly patients with newly diagnosed multiple myeloma: the IFM2021-01 teclille trial, cohort A. Blood. 2025;146(suppl 1):367. doi:10.1182/blood-2025-367
GUID : tag:audioboom.com,2025-12-22:/posts/8822536
Date de publication : 29/12/2025 à 14:00:00
